Американское общество гирудотерапии

Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms

Basic science / drug design published in Chem Sci (2025)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportРазработка лекарственных препаратовФармакология секрета слюнных желёзMaxwell JWC et al. · Chemical science, 2025

Abstract

Haematophagous organisms are a rich source of salivary anticoagulant polypeptides that exert their activity by blocking the catalytic site and one of two positively charged exosites on the host protease thrombin. Here, we describe a molecular engineering approach to hybridise post-translationally sulfated polypeptides from different blood-feeding organisms to enhance anticoagulant activity. This led to the discovery of a triply sulfated hybrid anticoagulant, XChimera, possessing fragments from flea, leech, and fly salivary polypeptides that exhibits femtomolar inhibitory activity against thrombin. The crystallographic structure of a complex of XChimera with thrombin shows that it displays a trivalent binding mode in which it simultaneously blocks three functional sites of the protease, the active site and exosites I and II. This trivalent chimera exhibited ultrapotent anticoagulant activity in a suite of in vitro clotting assays and was also shown to possess potent in vivo antithrombotic activity in a murine model of thrombosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Резюме

Engineering of XChimera, a triply-sulfated hybrid anticoagulant combining flea, leech, and fly salivary peptide fragments. Achieves femtomolar Ki against thrombin via trivalent binding (active site + exosites I & II). Crystal structure resolved; in vivo efficacy in murine thrombosis model.

Почему это важно для гирудотерапии

This study engineered a hybrid anticoagulant (XChimera) by combining sulfated salivary polypeptide fragments from flea, leech, and fly to achieve trivalent blockade of thrombin's active site and both exosites, yielding femtomolar inhibition. XChimera demonstrated potent anticoagulant activity in vitro and antithrombotic efficacy in a murine thrombosis model. For ASH's domain, this work highlights how leech-derived peptides can serve as modular building blocks in rational drug design of next-generation anticoagulants. However, the study is preclinical (in vitro and mouse model), and the leech component is only one of three hybridised fragments; the chimera is not a native leech secretome product and no clinical data are presented.

Цитирование

Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms.

Maxwell JWC et al. · Chemical science, 2025

Связанный клинический контекст

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.